NasdaqGM:ZYNE

Stock Analysis Report

Executive Summary

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company.

Snowflake

Fundamentals

Flawless balance sheet and fair value.

Share Price & News

How has Zynerba Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.6%

ZYNE

-0.07%

US Pharmaceuticals

1.0%

US Market


1 Year Return

39.3%

ZYNE

-7.0%

US Pharmaceuticals

8.0%

US Market

Return vs Industry: ZYNE exceeded the US Pharmaceuticals industry which returned -7% over the past year.

Return vs Market: ZYNE exceeded the US Market which returned 8% over the past year.


Shareholder returns

ZYNEIndustryMarket
7 Day0.6%-0.07%1.0%
30 Day-1.4%-1.6%-0.07%
90 Day-26.8%-1.7%-1.0%
1 Year39.3%39.3%-4.7%-7.0%10.4%8.0%
3 Year-29.9%-29.9%19.5%11.0%46.2%36.7%
5 Yearn/a22.0%9.2%64.3%46.2%

Price Volatility Vs. Market

How volatile is Zynerba Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Zynerba Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ZYNE ($8.01) is trading below our estimate of fair value ($217.18)

Significantly Below Fair Value: ZYNE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ZYNE is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: ZYNE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ZYNE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ZYNE is good value based on its PB Ratio (2.2x) compared to the US Pharmaceuticals industry average (2.9x).


Next Steps

Future Growth

How is Zynerba Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

66.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZYNE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZYNE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZYNE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ZYNE is forecast to have no revenue next year.

High Growth Revenue: ZYNE is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ZYNE is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Zynerba Pharmaceuticals performed over the past 5 years?

-35.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ZYNE is unprofitable, and losses have increased over the past 5 years at a rate of -35.7% per year.

Accelerating Growth: Unable to compare ZYNE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZYNE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: ZYNE has a negative Return on Equity (-41.92%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ZYNE is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ZYNE is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Zynerba Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ZYNE's short term assets ($93.6M) exceeds its short term liabilities ($10.0M)

Long Term Liabilities: ZYNE has no long term liabilities


Debt to Equity History and Analysis

Debt Level: ZYNE is debt free.

Reducing Debt: ZYNE has no debt compared to 5 years ago when its debt to equity ratio was 8.2%.


Balance Sheet

Inventory Level: ZYNE has a low level of unsold assets or inventory.

Debt Coverage by Assets: ZYNE's debt is not covered by short term assets (assets are -4551.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZYNE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ZYNE has sufficient cash runway for 1.853959 years if free cash flow continues to reduce at historical rates of -20% each year.


Next Steps

Dividend

What is Zynerba Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ZYNE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ZYNE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ZYNE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZYNE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ZYNE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Zynerba Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

4.0yrs

Average management tenure


CEO

Armando Anido (61yo)

5yrs

Tenure

US$2,001,096

Compensation

Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been Director of SCYNEXIS, Inc. since January 21, 2019. He has m ...


CEO Compensation Analysis

Compensation vs. Market: Armando's total compensation ($USD2.00M) is about average for companies of similar size in the US market ($USD1.18M).

Compensation vs Earnings: Armando's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.0yrs

Average Tenure

61yo

Average Age

Experienced Management: ZYNE's management team is considered experienced (4 years average tenure).


Board Age and Tenure

4.2yrs

Average Tenure

62.5yo

Average Age

Experienced Board: ZYNE's board of directors are considered experienced (4.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Armando Anido (61yo)

    Chairman & CEO

    • Tenure: 5yrs
    • Compensation: US$2.00m
  • Terri Sebree (61yo)

    President

    • Tenure: 5yrs
    • Compensation: US$1.28m
  • Will Roberts (50yo)

    VP of Investor Relations & Corporate Communications

    • Tenure: 2.3yrs
  • Jim Fickenscher (55yo)

    CFO, VP of Corporate Development & Treasurer

    • Tenure: 3.1yrs
    • Compensation: US$1.11m
  • Suzanne Hanlon (62yo)

    Secretary

    • Tenure: 5yrs
    • Compensation: US$791.52k
  • Joseph Palumbo

    Chief Medical Officer

    • Tenure: 0.2yrs

Board Members

  • Armando Anido (61yo)

    Chairman & CEO

    • Tenure: 5yrs
    • Compensation: US$2.00m
  • Ken Moch (64yo)

    Independent Director

    • Tenure: 4.2yrs
    • Compensation: US$160.61k
  • Dan Kisner (72yo)

    Independent Director

    • Tenure: 4.2yrs
    • Compensation: US$158.11k
  • Warren Cooper (66yo)

    Lead Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$179.48k
  • Bill Federici (59yo)

    Independent Director

    • Tenure: 4.2yrs
    • Compensation: US$166.86k
  • Jacqueline French

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • John Messenheimer

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Rodney Radtke

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Steven Siegel

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Pamela Stephenson (51yo)

    Director

    • Tenure: 0.7yrs

Company Information

Zynerba Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zynerba Pharmaceuticals, Inc.
  • Ticker: ZYNE
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$185.723m
  • Shares outstanding: 23.19m
  • Website: https://www.zynerba.com

Number of Employees


Location

  • Zynerba Pharmaceuticals, Inc.
  • 80 West Lancaster Avenue
  • Suite 300
  • Devon
  • Pennsylvania
  • 19333
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZYNENasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDAug 2015
6ZYDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2015

Biography

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neur ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 00:37
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.